Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once ...

Biogen’s salanersen has shown promise in slowing neuronal damage and opening new motor milestones, according to interim ...

Biogen's early-stage spinal muscular atrophy drug salanersen showed safety, motor improvements and 70% reduction in ...

Panelists discuss how spinal muscular atrophy is an autosomal recessive genetic disease affecting motor neurons with 3 ...

Panelists discuss how spinal muscular atrophy (SMA) treatment will evolve over the next 5 years, likely incorporating ...

Thiruvananthapuram: For the first time in India, pre-symptomatic treatment to an infant, diagnosed with spinal muscular ...

DataM Intelligence | competitive Intelligence Spinal Muscular Atrophy treatment is evolving fast, with gene therapy, oral drugs, and next-g ...

Biogen has pointed to an early readout from a small phase 1 trial as evidence that its antisense oligonucleotide salanersen ...

Newborn with SMA gene mutation receives presymptomatic treatment at SAT Hospital, a rare step in managing rare diseases.

At 1 month old, Stella Turnbull was diagnosed with spinal muscular atrophy and given weeks to live. She remained undeterred ...